Chair
Member
Audit Committee Position

Punit Dhillon

Mr. Dhillon is the co-founder and director of OncoSec Medical Incorporated, a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors. Prior to OncoSec, he served as Vice President of Finance and Operations at Inovio Pharmaceuticals, where he raised over $160 million through multiple financings and several licensing transactions. His management experience spans corporate finance, M&A integration, in-licensing of key intellectual property, strategy implementation, corporate transactions and collaborations with leading universities and key global opinion leaders. Mr. Dhillon also the co-founded BeCancerPositive.org, an online community for cancer patients. In 2014, he was a finalist in Ernst & Young’s “Entrepreneur of the Year” competition. Mr. Dhillon holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

Chair

Jim Heppell, LLB

Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies. His first fund, the Advantage Life Sciences I Fund, won the Canadian Venture Capital Deal of the Year Award in 2006. Earlier in his career, he practiced corporate securities law with Fasken Martineau DuMoulin and later served as President and CEO of Catalyst Corporate Finance Lawyers. Mr. Heppell has also helped to build a number of life science companies, including Aspreva Pharmaceuticals (acquired by Galenica Ltd. SW: GALN), Immgenics (acquired by Amgen NASDAQ: AMGN), Inovio Pharmaceuticals (NASDAQ: INO), and Sophiris Bio Inc. (NASDAQ: SPHS). He earned a BSc in microbiology and a law degree from the University of British Columbia.

Member

Audit Committee Charter

Download
Compensation Committee Position

Jim Heppell, LLB

Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies. His first fund, the Advantage Life Sciences I Fund, won the Canadian Venture Capital Deal of the Year Award in 2006. Earlier in his career, he practiced corporate securities law with Fasken Martineau DuMoulin and later served as President and CEO of Catalyst Corporate Finance Lawyers. Mr. Heppell has also helped to build a number of life science companies, including Aspreva Pharmaceuticals (acquired by Galenica Ltd. SW: GALN), Immgenics (acquired by Amgen NASDAQ: AMGN), Inovio Pharmaceuticals (NASDAQ: INO), and Sophiris Bio Inc. (NASDAQ: SPHS). He earned a BSc in microbiology and a law degree from the University of British Columbia.

Chair

Punit Dhillon

Mr. Dhillon is the co-founder and director of OncoSec Medical Incorporated, a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors. Prior to OncoSec, he served as Vice President of Finance and Operations at Inovio Pharmaceuticals, where he raised over $160 million through multiple financings and several licensing transactions. His management experience spans corporate finance, M&A integration, in-licensing of key intellectual property, strategy implementation, corporate transactions and collaborations with leading universities and key global opinion leaders. Mr. Dhillon also the co-founded BeCancerPositive.org, an online community for cancer patients. In 2014, he was a finalist in Ernst & Young’s “Entrepreneur of the Year” competition. Mr. Dhillon holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

Member

Compensation Committee Charter

Download
Nominating and Corporate Governance Committee Position

Jim Heppell, LLB

Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies. His first fund, the Advantage Life Sciences I Fund, won the Canadian Venture Capital Deal of the Year Award in 2006. Earlier in his career, he practiced corporate securities law with Fasken Martineau DuMoulin and later served as President and CEO of Catalyst Corporate Finance Lawyers. Mr. Heppell has also helped to build a number of life science companies, including Aspreva Pharmaceuticals (acquired by Galenica Ltd. SW: GALN), Immgenics (acquired by Amgen NASDAQ: AMGN), Inovio Pharmaceuticals (NASDAQ: INO), and Sophiris Bio Inc. (NASDAQ: SPHS). He earned a BSc in microbiology and a law degree from the University of British Columbia.

Chair

Punit Dhillon

Mr. Dhillon is the co-founder and director of OncoSec Medical Incorporated, a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors. Prior to OncoSec, he served as Vice President of Finance and Operations at Inovio Pharmaceuticals, where he raised over $160 million through multiple financings and several licensing transactions. His management experience spans corporate finance, M&A integration, in-licensing of key intellectual property, strategy implementation, corporate transactions and collaborations with leading universities and key global opinion leaders. Mr. Dhillon also the co-founded BeCancerPositive.org, an online community for cancer patients. In 2014, he was a finalist in Ernst & Young’s “Entrepreneur of the Year” competition. Mr. Dhillon holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

Member

Nominating and Corporate Governance Committee Charter

Download
Finance and Business Development Committee Position

Punit Dhillon

Mr. Dhillon is the co-founder and director of OncoSec Medical Incorporated, a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors. Prior to OncoSec, he served as Vice President of Finance and Operations at Inovio Pharmaceuticals, where he raised over $160 million through multiple financings and several licensing transactions. His management experience spans corporate finance, M&A integration, in-licensing of key intellectual property, strategy implementation, corporate transactions and collaborations with leading universities and key global opinion leaders. Mr. Dhillon also the co-founded BeCancerPositive.org, an online community for cancer patients. In 2014, he was a finalist in Ernst & Young’s “Entrepreneur of the Year” competition. Mr. Dhillon holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

Chair

Jim Heppell, LLB

Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies. His first fund, the Advantage Life Sciences I Fund, won the Canadian Venture Capital Deal of the Year Award in 2006. Earlier in his career, he practiced corporate securities law with Fasken Martineau DuMoulin and later served as President and CEO of Catalyst Corporate Finance Lawyers. Mr. Heppell has also helped to build a number of life science companies, including Aspreva Pharmaceuticals (acquired by Galenica Ltd. SW: GALN), Immgenics (acquired by Amgen NASDAQ: AMGN), Inovio Pharmaceuticals (NASDAQ: INO), and Sophiris Bio Inc. (NASDAQ: SPHS). He earned a BSc in microbiology and a law degree from the University of British Columbia.

Member

Finance and Business Development Committee Charter

Download

Punit Dhillon

Mr. Dhillon is the co-founder and director of OncoSec Medical Incorporated, a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors. Prior to OncoSec, he served as Vice President of Finance and Operations at Inovio Pharmaceuticals, where he raised over $160 million through multiple financings and several licensing transactions. His management experience spans corporate finance, M&A integration, in-licensing of key intellectual property, strategy implementation, corporate transactions and collaborations with leading universities and key global opinion leaders. Mr. Dhillon also the co-founded BeCancerPositive.org, an online community for cancer patients. In 2014, he was a finalist in Ernst & Young’s “Entrepreneur of the Year” competition. Mr. Dhillon holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

Jim Heppell, LLB

Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies. His first fund, the Advantage Life Sciences I Fund, won the Canadian Venture Capital Deal of the Year Award in 2006. Earlier in his career, he practiced corporate securities law with Fasken Martineau DuMoulin and later served as President and CEO of Catalyst Corporate Finance Lawyers. Mr. Heppell has also helped to build a number of life science companies, including Aspreva Pharmaceuticals (acquired by Galenica Ltd. SW: GALN), Immgenics (acquired by Amgen NASDAQ: AMGN), Inovio Pharmaceuticals (NASDAQ: INO), and Sophiris Bio Inc. (NASDAQ: SPHS). He earned a BSc in microbiology and a law degree from the University of British Columbia.

Jim Heppell, LLB

Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies. His first fund, the Advantage Life Sciences I Fund, won the Canadian Venture Capital Deal of the Year Award in 2006. Earlier in his career, he practiced corporate securities law with Fasken Martineau DuMoulin and later served as President and CEO of Catalyst Corporate Finance Lawyers. Mr. Heppell has also helped to build a number of life science companies, including Aspreva Pharmaceuticals (acquired by Galenica Ltd. SW: GALN), Immgenics (acquired by Amgen NASDAQ: AMGN), Inovio Pharmaceuticals (NASDAQ: INO), and Sophiris Bio Inc. (NASDAQ: SPHS). He earned a BSc in microbiology and a law degree from the University of British Columbia.

Punit Dhillon

Mr. Dhillon is the co-founder and director of OncoSec Medical Incorporated, a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors. Prior to OncoSec, he served as Vice President of Finance and Operations at Inovio Pharmaceuticals, where he raised over $160 million through multiple financings and several licensing transactions. His management experience spans corporate finance, M&A integration, in-licensing of key intellectual property, strategy implementation, corporate transactions and collaborations with leading universities and key global opinion leaders. Mr. Dhillon also the co-founded BeCancerPositive.org, an online community for cancer patients. In 2014, he was a finalist in Ernst & Young’s “Entrepreneur of the Year” competition. Mr. Dhillon holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

Jim Heppell, LLB

Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies. His first fund, the Advantage Life Sciences I Fund, won the Canadian Venture Capital Deal of the Year Award in 2006. Earlier in his career, he practiced corporate securities law with Fasken Martineau DuMoulin and later served as President and CEO of Catalyst Corporate Finance Lawyers. Mr. Heppell has also helped to build a number of life science companies, including Aspreva Pharmaceuticals (acquired by Galenica Ltd. SW: GALN), Immgenics (acquired by Amgen NASDAQ: AMGN), Inovio Pharmaceuticals (NASDAQ: INO), and Sophiris Bio Inc. (NASDAQ: SPHS). He earned a BSc in microbiology and a law degree from the University of British Columbia.

Punit Dhillon

Mr. Dhillon is the co-founder and director of OncoSec Medical Incorporated, a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors. Prior to OncoSec, he served as Vice President of Finance and Operations at Inovio Pharmaceuticals, where he raised over $160 million through multiple financings and several licensing transactions. His management experience spans corporate finance, M&A integration, in-licensing of key intellectual property, strategy implementation, corporate transactions and collaborations with leading universities and key global opinion leaders. Mr. Dhillon also the co-founded BeCancerPositive.org, an online community for cancer patients. In 2014, he was a finalist in Ernst & Young’s “Entrepreneur of the Year” competition. Mr. Dhillon holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

Punit Dhillon

Mr. Dhillon is the co-founder and director of OncoSec Medical Incorporated, a leading biopharmaceutical company developing cancer immunotherapies for the treatment of solid tumors. Prior to OncoSec, he served as Vice President of Finance and Operations at Inovio Pharmaceuticals, where he raised over $160 million through multiple financings and several licensing transactions. His management experience spans corporate finance, M&A integration, in-licensing of key intellectual property, strategy implementation, corporate transactions and collaborations with leading universities and key global opinion leaders. Mr. Dhillon also the co-founded BeCancerPositive.org, an online community for cancer patients. In 2014, he was a finalist in Ernst & Young’s “Entrepreneur of the Year” competition. Mr. Dhillon holds a BA (Honors) in political science and a minor in business administration from Simon Fraser University.

Jim Heppell, LLB

Mr. Heppell is the co-founder, President and Director of BC Advantage Funds (VCC) Ltd., a venture fund that invests in and builds technology, life science and clean technology companies. His first fund, the Advantage Life Sciences I Fund, won the Canadian Venture Capital Deal of the Year Award in 2006. Earlier in his career, he practiced corporate securities law with Fasken Martineau DuMoulin and later served as President and CEO of Catalyst Corporate Finance Lawyers. Mr. Heppell has also helped to build a number of life science companies, including Aspreva Pharmaceuticals (acquired by Galenica Ltd. SW: GALN), Immgenics (acquired by Amgen NASDAQ: AMGN), Inovio Pharmaceuticals (NASDAQ: INO), and Sophiris Bio Inc. (NASDAQ: SPHS). He earned a BSc in microbiology and a law degree from the University of British Columbia.